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Abstract: In a continuation of our computational efforts to find new natural inhibitors of
a variety of target enzymes from parasites causing neglected tropical diseases (NTDs), we now
report on 15 natural products (NPs) that we have identified as inhibitors of Leishmania major
pteridine reductase I (LmPTR1) through a combination of in silico and in vitro investigations.
Pteridine reductase (PTR1) is an enzyme of the trypanosomatid parasites’ peculiar folate metabolism,
and has previously been validated as a drug target. Initially, pharmacophore queries were created
based on four 3D structures of LmPTR1 using co-crystallized known inhibitors as templates.
Each of the pharmacophore queries was used to virtually screen a database of 1100 commercially
available natural products. The resulting hits were submitted to molecular docking analyses in
the substrate binding site of the respective protein structures used for the pharmacophore design.
This approach led to the in silico identification of a total of 18 NPs with predicted binding affinity
to LmPTR1. These compounds were subsequently tested in vitro for inhibitory activity towards
recombinant LmPTR1 in a spectrophotometric inhibition assay. Fifteen out of the 18 tested compounds
(hit rate = 83%) showed significant inhibitory activity against LmPTR1 when tested at a concentration
of 50 µM. The IC50 values were determined for the six NPs that inhibited the target enzyme by more
than 50% at 50 µM, with sophoraflavanone G being the most active compound tested (IC50 = 19.2 µM).
The NPs identified and evaluated in the present study may represent promising lead structures for
the further rational drug design of more potent inhibitors against LmPTR1.
Keywords: Leishmania major; cutaneous Leishmaniasis; pteridine reductase I inhibitor; natural product;
in silico screening
1. Introduction
In continuation of our combined in silico/in vitro studies to find natural products inhibiting
vital target enzymes of protozoan parasites [1,2], we have now focused on Leishmania major pteridine
reductase I (LmPTR1), which has previously been suggested as a drug target [3]. As the etiological
agents of several neglected tropical diseases (NTDs), parasites of the group Trypanosomatidae,
including such of the genus Leishmania, are responsible for a significant disease burden, especially for
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rural populations in tropical regions living under poor socioeconomic conditions. Leishmaniasis is
caused by various species of Leishmania, which lead to different clinical forms of the disease. It threatens
the health of nearly one billion people worldwide [4]; an annual number of about 700,000 to one million
cases are reported according to the World Health Organization [5]. As such, CL represents a global
health problem of high relevance [5]. Leishmania major (Lm) is one of the species causing cutaneous
Leishmaniasis (CL). CL is characterized by an often subacute progression, and while responsible for
a relatively low rate of fatality, this most common form of Leishmania infection leads to severe and
disfiguring skin lesions [6].
Lm, as all Leishmania species, is an intracellular parasite; as a result, the research for vaccines has not
been successful, and chemotherapeutics are the only option for fighting the disease [7]. Problematically,
all of the available compounds for the treatment of Leishmaniasis, and CL in particular, suffer from
severe drawbacks such as high toxicity, lack of efficacy, or the need for hospitalization [5]. Additionally,
their mechanisms of action are mostly unknown, and shortcomings concerning their administration,
such as intravenous and long-lasting therapy regimes, additionally hamper therapy in rural and
underdeveloped populations. These circumstances are severely limiting the current therapy of CL,
underlining the urgent need for innovative chemotherapeutic options to sufficiently treat CL.
Due to fundamental phylogenetic differences between mammals and members of the Trypanosomatidae
group, several metabolic pathways and their corresponding enzymes have been identified as potential
targets for antileishmanial therapies in the past decades [8]. In particular, the peculiar folate metabolism
of the Leishmania species has increasingly attracted interest as a promising starting point for innovative
therapies [9,10]. Although inhibitors of the dihydrofolate reductase (DHFR, catalyzing the hydration
of folic acid to di- and tetrahydro folic acid) are successfully used in therapy, e.g., malaria [11],
Leishmania species show resistance against common antifolates such as methotrexate (MTX). Pteridine
reductase I (PTR1), an oxidoreductase unique to kinetoplastids, is considered responsible for this
DHFR resistance because it allows the parasites to produce reduced folates in an alternative pathway,
thus compensating for the inhibition of DHFR. Under physiological conditions, PTR1 contributes
about 10% to the production of the needed folate equivalents [12]. In the course of reduced DHFR
activity, a PTR1 upregulation can be observed in members of the genus Leishmania, rendering these
parasites resistant to this therapeutic strategy [12]. Targeting PTR1, especially in combination with
DHFR inhibition, could therefore lead to effective and innovative antileishmanial chemotherapies.
At present, however, no inhibitors of leishmanial PTR1 are available as therapeutic options.
In the present study, we report on the identification of several natural products (NPs) as inhibitors
of Leishmania major pteridine reductase I (LmPTR1) by in silico screening (pharmacophore-based
virtual screening and docking simulations) followed by experimental evaluation of the resulting hits
in a spectrophotometric inhibition assay with recombinant LmPTR1.
2. Results
2.1. In Silico Identification of Natural Products as Potential LmPTR1 Inhibitors
A database of commercially available natural products supplied by PhytoLab GmbH & Co.
KG (Vestenbergsgreuth, Germany; http://phyproof.phytolab.de/), which consisted of 1100 entries,
was used as compound collection for the in silico prediction of possible inhibitors against LmPTR1
by means of pharmacophore-based virtual screening followed by docking simulations. All of
the computations were performed with the software package MOE [13]. Initially, compounds not
likely to have drug-like properties were eliminated from the database employing Lipinski’s rule of
five [14], resulting in a final database size of 737 NPs. 3D models of the remaining structures were
generated and subjected to geometry optimization by means of a conformational search. A maximum
of the 10 energetically most favorable conformers of each compound were stored for subsequent
virtual screening.
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Four protein structures of pteridine reductase 1 from Leishmania major, each co-crystallized
with a molecule of the oxidized co-substrate nicotinamide adenine dinucleotide (NADP+) and
an inhibitor molecule, were retrieved from the Protein Data Bank (PDB) [15] (PDB-IDs are reported
in the experimental section) and subjected to structural correction and energy minimization.
The co-crystallized inhibitors (see Figures 1–4) of the four protein models elucidated by X-ray
crystallography subsequently served as templates for the creation of four independent pharmacophore
queries (see Supplementary Materials Figures S1–S4; for a detailed description of the pharmacophore
generation, see Section 3.4). Each of the four pharmacophores was then used as a virtual screening filter
for the NPs database yielding hit collections, which were subsequently docked into the corresponding
inhibitor binding site of the protein structure from which the respective pharmacophore query had
been obtained, employing a fast rigid docking algorithm. The resulting docking poses were ranked by
their docking scores (S-scores, in kcal/mol; more negative scores indicating higher binding affinity).
The 10 compounds with the most negative S-scores were selected in each case for a more refined
docking simulation (i.e., induced fit docking algorithm, allowing flexibility for the docked ligand as
well as the binding site). Five compounds with the most negative S-scores in the induced fit docking
with each protein structure were considered promising candidates for in vitro evaluation. Figures 1–4
show these best hits obtained for each of the four pharmacophores/protein structures, as well as
the respective co-crystallized inhibitors used to construct the pharmacophore queries. The calculated
S-scores (given in kcal/mol) are also reported in Figures 1–4.
Figure 1. Best five hits from the virtual screening based on the CB3 pharmacophore with
the Leishmania major pteridine reductase I (LmPTR1) Protein Data Bank (PDB) identification (ID) “2BFA”;
S-scores of the induced-fit docking simulations are given in kcal/mol. A “self-docking” computation of
the co-crystallized inhibitor CB3 was performed accordingly.
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Figure 2. Best five hits from the virtual screening based on the trimethoprim pharmacophore
(LmPTR1 PDB-ID “2BFM”); S-scores of the induced-fit docking simulations are given in kcal/mol.
A “self-docking” computation of the co-crystallized inhibitor trimethoprim was performed accordingly.
Figure 3. Best five hits from the virtual screening based on the FE1 pharmacophore (LmPTR1 PDB-ID
“2QHX”); S-scores of the induced-fit docking simulations are given in kcal/mol. A “self-docking”
computation of the co-crystallized inhibitor FE1 was performed accordingly.
Molecules 2017, 22, 2166 5 of 14
Figure 4. Best five hits from the virtual screening based on the DVP pharmacophore (LmPTR1 PDB-ID
“3H4V”); S-scores of the induced-fit docking simulations are given in kcal/mol. A “self-docking”
computation of the co-crystallized inhibitor DVP was performed accordingly.
It is interesting to note that despite the considerable structural diversity of the investigated NPs
(including many non-aromatic compounds such as terpenoids of various sizes), all of the selected
hits are aromatic compounds. Most of them are flavonoids, but two lignans, some caffeic acid esters,
one xanthone, and one monomeric phenylpropanoid are also included. Two compounds (silybin A
and rosmarinic acid) were among the best five hits in two of the four cases, so that in total, 18 NPs
were obtained from the manufacturer for experimental evaluation.
2.2. In Vitro Evaluation of the Identified NPs against LmPTR1
In order to assess the inhibitory activity of the compounds identified in silico, spectrophotometric
inhibition assays were performed on recombinant LmPTR1, measuring the decreasing concentration of
NADPH at 340 nm as a linear kinetic parameter for LmPTR1 activity at saturating concentrations of
NADPH (co-substrate) and folic acid (substrate). First, each in silico hit was added to a concentration
of 50 µM, and the resulting linear plots of absorbance vs. time were compared with those recorded in
the absence of an inhibitor. Of the 18 compounds predicted in silico as potential inhibitors, 15 indeed
showed significant inhibitory activity at 50 µM (hit rate = 83%). The results of the in vitro assays are shown
in Table 1. Six compounds, namely 2,3-dehydrosilybin A (1; a flavonolignan from Silybum marianum,
Asteraceae [16]), apigenin-7-glucoside (2; a glycosylated flavone occurring e.g., in Matricaria recutita,
Asteraceae [17]), garcinone C (3; a xanthone derivative naturally found in Garcinia mangostana,
Clusiaceae [18]), myricetin (4; a flavonol occurring widespread in plants, e.g., in Vitis vinifera, Vitaceae [19]),
salvianolic acid A (5; a caffeic acid derivative from Salvia species, Lamiaceae [20]) and sophoraflavanone
G (6; a flavanone isolated e.g., from Sophora flavescens, Fabaceae [21]) inhibited the target enzyme by
more than 50% at 50 µM. For these most active inhibitors, concentration-effect curves were determined,
from which IC50 values could be determined in five cases. For 2,3-dehydrosilybin A (1), complete
inhibition could not be achieved. The maximum of inhibition achieved with this compound was 64%
at a concentration of 50 µM. This turned out to be due to the limited solubility of 1 under the assay
conditions, so that in this case, an EC50 value was determined. Plots of the inhibitory activity as a function
of concentration for compounds 1 to 6 are shown in the Supplementary Materials Figures S10–S15,
and the resulting IC50 and EC50 values are reported in Table 1.
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Table 1. Inhibitory activity of the in silico hits on LmPTR1. Data represents inhibition values in %
at 50 µM (n.i. = no inhibition at 50 µM), and IC50 values of compounds with >50% inhibition at this
concentration in µM (in brackets: 95% confidence interval; n = 4 to 7).
Compound % Inhibition at c = 50 µM IC50 (µM)
(−)-epicatechin-3-gallate 24
2,3-dehydrosilybin A (1) 66 7.3 (5.6–9.5) (EC50)
apigenin-7-glucoside (2) 60 43.5 (39.1–48.2)
eleutheroside B 12
garcinone C (3) 74 26.3 (21.0–33.0)
icariside II 35
isosakuranetin n.i.
isosilybin B 26
isoxanthohumol 22
magnolin n.i.
myricetin (4) 68 21.0 (18.3–24.2)
phillyrin n.i.
rosmarinic acid 20
salvianolic acid A (5) 67 42.2 (38.3–46.6)
silybin A 14
silybin B 19
silychristin 24
sophoraflavanone G (6) 90 19.2 (17.1–21.6)
Five of the most active NPs (1–4 and 6) identified are structurally related to some extent, sharing
a chromane (3 and 6) or chromene (1, 2 and 4) system as a common skeletal element. These moieties
are partially comparable to the pteridine system of the natural substrate folic acid, rendering these
compounds promising initial hits for further inhibitor development and optimization. These findings
are in agreement with recently published data from Borsari et al. [22], who also identified flavonoid
derivatives as inhibitors of Lm as well as TbPTR1 by a combined target-based phenotypic screening
based on a library of natural products.
2.3. Mechanistic Considerations
The substrate-binding domain of LmPTR1 is characterized by a considerable degree of lipophilicity,
especially in a part mainly made up by hydrophobic amino acids like Tyr, Phe, Leu, or Val.
The NADPH/NADP+-binding part of the catalytic site, on the other hand, is characterized by more
hydrophilic amino acids and more polar properties overall. Due to the close vicinity of the co-substrate
and substrate binding sites, the co-substrate NADPH/NADP+ may also contribute to the properties
of the substrate cavity, introducing the possibility of polar interactions with a ligand bound in
the folic acid binding site. Up to the end of this study, there were no crystal structures of LmPTR1
available in complex with the substrate folic acid. In order to allow comparative analyses between
the calculated docking poses of the NP inhibitors identified in this study, a protein structure model with
co-crystallized dihydrobiopterin (DHB; PDB-ID “2BF7” [23]) was also investigated. DHB is substrate
of PTR1 [24], and a structural analog of folic acid, with which it shares the pteridine system as the most
important structural feature, and may hence allow at least a partial comparison to the expected binding
mode of the natural ligand. Figure 5 shows the folic acid binding site of PDB-ID “2BF7” in complex
with DHB and NADP+.
The docking simulations of all six NPs identified as most active (1–6, see Figures 6 and 7 as well
as Supplementary Materials Figures S5–S8) revealed favorable binding modes in the folic acid cavity
of LmPTR1, fitting the available space very well in each case. It is interesting to note that the best
docking poses of all six NPs show some similarity with the experimentally determined binding
mode of DHB (PDB-ID “2BF7”, Figure 5). In the case of DHB, the pteridine moiety is bound near
the nicotinamide partial structure of NADP+, and presents a pi–pi interaction with the pyrimidine
heterocycle of the co-substrate. Additionally, two hydrogen bonds are formed between both, the amino
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group at C-3 and the NH in position 2 of the pteridine heterocycle with a phosphate group of
NADP+. This interaction profile including both the pi–pi interaction with the nicotinamide moiety
and the H-bond formation with one phosphate group of NAPD+ can also be observed in each of
the best docking poses of inhibitors 1–6 (Figures 6 and 7 show the best docking poses for the two most
active inhibitors, 1 and 6, respectively. Analogous representations of compounds 2–5 are presented
in the Supplementary Materials information, Figures S5–S8), indicating that these interactions are of
considerable importance for the rational design of compounds inhibiting LmPTR1.
It is interesting to note that apart from salvianolic acid A (5), the most active inhibitors share
structural features with certain similarities, such as engaging in pi–pi interactions with the nicotinamide
moiety, namely, a flavone (2), a flavonol (1, 4), a flavanone (6) or a four-chromanone system (3).
These partially aromatic ring systems are to some extent comparable to the pteridine structure of
the natural substrate folic acid and were predicted in the docking simulations to display a very
similar binding mode as the dihydropteridine part of DHB (e.g., in LmPTR1, PDB-ID “2BF7”) by
means of the formation of a pi–pi stacking interaction with the nicotinamide moiety of the co-substrate.
The mentioned interactions were also predicted in silico for 5, but are in this case mediated by one of
the dihydroxybenzene moieties.
Figure 5. Representation of the catalytic site of LmPTR1 (PDB-ID “2BF7”), with the co-crystallized
nicotinamide adenine dinucleotide (NADP+) shown in yellow, and the co-crystallized substrate
dihydrobiopterin (DHB) (7,8-dihydrobiopterin) shown in cyan. (A) The molecular surface of
the binding site was colored according to lipophilicity, with green indicating high lipophilicity,
and purple indicating low lipophilicity. Note the pi-stacking interaction of the pteridine system with
the nicotinamide moiety of NADP+, as well as the formation of H-bonds with one phosphate group of
the co-crystallized co-substrate; (B) Surface not shown, but amino acid residues labeled.
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Figure 6. Best calculated docking pose of 2,3-dehydrosilybin A (1) in the folic acid binding site of
LmPTR1 (PDB-ID “2BFM”), with the co-crystallized NADP+ shown in yellow, and the best docking pose
of 1 shown in cyan. (A) The molecular surface of the binding site was colored according to lipophilicity,
with green indicating high lipophilicity, and purple indicating low lipophilicity; (B) Surface not shown,
but amino acid residues labeled.
It is also worth mentioning that due to the lipophilic character of the substrate binding site of
LmPTR1, hydrophobic substituents could improve the inhibitory activity of NPs against LmPTR1.
In the cases of sophoraflavanone G (6; see Figure 7) and garcinone C (3; see Figure S6), lipophilic prenyl
side chains were present, which were not surprisingly placed by the docking algorithm in the most
lipophilic part of the folic acid binding site. For 3 and 6, the in silico postulated position of their
lipophilic side chains is very similar, with both of them lying in the vicinity of Leu 188 and Leu 226.
Thus, the hydrophobic interactions of these structural elements may contribute to the LmPTR1 inhibitory
activity of 3 and 6.
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Figure 7. Best calculated docking pose of sophoraflavanone G (6) in the folic acid binding site of
LmPTR1 (PDB-ID “3H4V”), with the co-crystallized NADP+ shown in yellow, and the best docking
pose of 6 shown in cyan. (A) Rendered surfaces are colored according to lipophilicity, with green
indicating high lipophilicity, and purple indicating low lipophilicity; (B) Surface not shown, but amino
acid residues labeled.
3. Materials and Methods
3.1. In Silico Modelling
All in silico operations, i.e., database and structure optimization, protein preparation,
pharmacophore generation, and virtual screening, as well as all docking simulations, were performed
with the Molecular Operating Environment (MOE), software version 2011.10 [13].
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3.2. Database Design
The NP database used for the present study consisted of 1100 natural compounds of various origins,
as available from PhytoLab GmbH & Co. KG (Vestenbergsgreuth, Germany; http://phyproof.phytolab.de/).
The database entries were filtered according to Lipinski’s rule of five [14], and non-drug-like compounds
(i.e., structures violating more than one of Lipinski’s rules) were discarded. 3D models of the remaining 737
compounds were generated and subjected to geometry optimization using the force field MMFF94x and low
mode molecular dynamics conformational search (LowModeMD), in order to determine the most favorable
conformations. A maximum of 10 low energy conformations of each NP within an energy window of 3
kcal/mol above the lowest energy conformer were collected in a new database, which served as compound
collection for the subsequent virtual screening approach.
3.3. Acquisition and Preparation of the Protein’s 3D-Structure
Five 3D structures of pteridine reductase 1 from Leishmania major were retrieved from the Protein
Data Bank (PDB-IDs “2BF7”, “2BFA”, “2BFM”, “2QHX”, and “3H4V”). The structures were subsequently
corrected (with the structure preparation in MOE correcting terminal amino acids and protonation
states, as well as faulty or misassigned amino acids) and energy was minimized using the MMFF94x
force field [25] (an iterative minimization was employed, i.e., a series of minimizations were performed
tethering heavy atoms with force constants ranging from 100 to 0 (100, 10, 1, 0.1, and 0)). All further steps
were carried out with the fully relaxed protein structures containing, in each case, the co-crystallized
co-substrate NADP+ and an inhibitor molecule, as well as a variable number of water molecules.
3.4. Pharmacophore Design and Virtual Screening
Based on the co-crystallized inhibitors of the four protein models “2BFA”, “2BFM”, “2QHX”,
and “3H4V”, pharmacophore queries were created in order to perform virtual screenings on the natural
product database. Initially, the interactions between the enzyme and the co-crystallized inhibitors
in the active site were analyzed by creating an interaction table based on the “ligand interactions”
feature implemented in MOE. Every interaction yielding a calculated S-score of less than or equal
to −1 kcal/mol was considered to be of relevance for the inhibitors’ binding, and was therefore
included into the pharmacophore query as a feature sphere. The radii of the feature spheres ranged
from 1 to 2 Å, depending on the represented moiety (e.g., aromatic rings around 2 Å, and H-bond
donors and acceptors around 1 Å, as suggested by MOE). Additionally, the surface of the binding
site was also analyzed in order to detect potential further interaction sites not already addressed by
the co-crystallized inhibitor. To achieve this, surface representations of the active site were calculated
(e.g., through the electrostatic maps feature implemented in MOE), and potential further interactions
of interest were included as additional feature spheres. The queries thus generated comprised five to
seven features. Additionally, so-called “exclusion spheres” were added as features for every atom
of the protein (radius of 1.42 Å, solvent molecules excluded) to rule out compounds that might be
in agreement with the pharmacophore features, but would collide with the protein’s amino acids.
The pharmacophore queries thus obtained are depicted in Supplementary Materials Figures S1–S4
(exclusion spheres not shown). Each of the queries was then used to virtually screen the NP database.
In order to achieve a hit rate suitable for further in silico and in vitro analyses, the mentioned queries
were only partially applied to a predefined extent (“partial match” feature in MOE), generating hit
rates between 10 and 50 compounds for each pharmacophore, which were then collected into new
databases and subsequently submitted to docking simulations.
3.5. Docking Simulations
The hits of each pharmacophore screening were submitted to molecular docking simulations.
In order to ensure a valid docking protocol for each protein structure, the respective co-crystallized
inhibitors were subjected to a self-docking simulation in the induced fit mode (i.e., both the ligand
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and the amino acid side chains in the docking site were allowed to change their geometry in order
to achieve an optimal fit). In all of the cases, good reproducibility of the co-crystallized inhibitor
conformation (Root mean square (RMS) deviation after superposition of the best calculated docking
pose and the experimental co-crystallized conformation <1 Å) was achieved. These self-docking
experiments also yielded docking scores (S-scores in kcal/mol) for the known inhibitors, which could
then be compared with those of the natural product hits (see below). The hits from the four databases
that resulted from the virtual screenings described above were all docked into the respective inhibitor
binding sites of the four protein structures by means of a rigid docking algorithm (i.e., allowing
flexibility only of the investigated compounds, and not of the binding pocket). The 10 docking poses
of each molecule from each series were collected into new databases and ranked by their S-scores.
The 10 compounds yielding the most negative S-scores were then submitted to an induced-fit docking
simulation, conceding flexibility to the investigated ligands as well as the corresponding binding sites.
The resulting most favorable docking poses and their calculated S-scores were again collected into
new databases and ranked by their S-scores. The five NPs with the most favorable docking scores in
each of the four series were selected as candidates for experimental evaluation by an in vitro enzyme
inhibition assay.
3.6. Tested Compounds
All of the tested natural products were generously donated by PhytoLab GmbH & Co. KG
(Vestenbergsgreuth, Germany).
3.7. Transformation of E. coli Cells (BL21 (DE3)) with Vector System LmPTR1-pET-15b
The pET-15b vector system containing the poly-His-LmPTR1 gene together with a carbenicillin
resistance selection marker was previously described [22]. Initially, the supplied vector was heat
shock-transformed into competent E. coli cells (BL21 (DE3)). To do so, an aliquot of BL21 (DE3)
cells was incubated together with 1–2 ng of plasmide at 42 ◦C for 90 s, followed by cooling on
ice for 1 min and the subsequent addition of 1 mL of SOC medium (Super Optimal Catabolite
medium, containing 20 g/L tryptone/peptone, 5 g/L yeast extract, 0.5 g/L NaCl, 2.5 g/L KCl, 20 mM
D-glucose, and 10 mM MgCl2). After 1.5 h of incubation (37 ◦C, 200 rpm), 200 µL of the culture
were transferred to an agar plate containing carbenicillin (50 µg/mL) and incubated overnight at
37 ◦C. A single culture was afterwards randomly selected and plated on another carbenicillin agar
plate. After incubation overnight, the complete bacterial growth was collected using a sterile cotton
swab and PP medium (proteose peptone medium, containing 15 g/L peptone, 5 g/L NaCl, 1 g/L
Zulkowsky starch, 1 g/L KH2PO4, 0.8 g/L K2HPO4, and 20% (v/v) glycerol) was added. The yielded
suspension was afterwards transferred to a sterile vessel filled with glas cryoperls, rapidly frozen with
an ethanol/dry ice mixture, and stored at −80 ◦C.
3.8. Recombinant Expression and Purification of LmPTR1
For the heterologous expression of LmPTR1, an overnight culture of the transformed E. coli
BL21 (DE3) cells mentioned above was used to inoculate 2 L Erlenmeyer flasks filled with 400 mL of
an LB medium containing carbenicillin (50 µg/mL carbenicillin), which were afterwards incubated
until reaching an optical density (OD600nm) of 0.6 to 0.8 (incubation of 4–6 h at 37 ◦C). The expression
of the poly-His tagged target protein was subsequently induced by the addition of 0.4 mM
isopropyl-ß-D-thiogalactopyranoside (IPTG). After overnight incubation at 20 ◦C for 14 to 16 h,
centrifugation at 4 ◦C and 5000 rpm was performed for 10 min. The resulting bacterial pellet was
resuspended in lysis buffer (50 mM Tris/HCl (pH 7.6), 250 mM NaCl) with added lysozyme (1 mg/mL),
phenylmethanesulfonyl fluoride (PMSF, 1 mM), and benzamidine (1 mM), and was afterwards treated
with ultrasonic pulses while stored on ice. Another centrifugation was carried out for 45 min at
15.000 rpm and 4 ◦C. The yielded supernatant was passed through a syringe filter (pore size 0.22 µm)
and submitted to a nitrilotriacetate-nickel (NTA-Ni2+) loaded column. After washing the column,
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the target protein was eluted by the application of different imidazole-containing buffers (100–500 mM).
The yielded fractions were subsequently analyzed by SDS-PAGE. Fractions containing the target
protein without major impurities were afterwards pooled and submitted to dialysis (50 mM Tris/HCl
(pH 7.6), 100 mM NaCl, 4 ◦C, and constant stirring) overnight. After the addition of glycerol as
a cryoprotector (final concentration of 20%), the concentration, saturating conditions of substrate
and co-substrate, and the activity of LmPTR1 were subsequently assessed by optical spectroscopy
([LmPTR1] = 2375 µg/mL; specific activity of 0.24 U/mg LmPTR1, tested in the presence of NADPH
and folic acid at saturating conditions ([NADPH] = 250 µM, [folic acid] = 22.5 µM)). The yielded
protein solution was stored at −80 ◦C in aliquots of 500 µL. The diagrams depicting the determination
of the saturating conditions of folic acid and NADPH are shown in Supplementary Materials Figure S9.
3.9. LmPTR1-Inhibition Assay
The determination of the inhibitory activity of the in silico hits was carried out by a UV-Vis
spectrophotometric assay on recombinantly produced LmPTR1. In order to assess the catalytic
activity of LmPTR1, the oxidation of NADPH to NADP+ was followed with a Hitachi U-2900
UV-Vis spectrophotometer at 340 nm as a linear kinetic parameter. Reference measurements without
the addition of inhibitors were used to determine the full catalytic activity (100% value), and subsequent
measurements with inhibitory compounds were calculated accordingly. The total assay volume of
1 mL consisted of sodium phosphate buffer (50 mM NaH2PO4, 100 mM NaCl, pH 6), 250 µM NADPH,
35 µg LmPTR1, 22.5 µM folic acid, and varying inhibitor concentrations. The tested inhibitors were
dissolved in DMSO (10 mM stock solutions), and appropriate volumes were added to the assays
to obtain the desired assay concentrations in such a way that a DMSO concentration between
0.1–1% resulted. No inhibition of LmPTR1 could be detected by DMSO itself at the mentioned
concentrations. Initial tests were performed at an inhibitor concentration of 50 µM in triplicate. In case
of an inhibitory activity above 50% at this concentration, concentration-effect curves were obtained
by testing four to seven different inhibitor concentrations (each of them measured in triplicate) and
employing non-linear regression analysis with the software GraphPad Prism 3.0 to determine IC50
values (or an EC50 value in the case of compound 1, due to its limited solubility in the employed assay
system). The concentration-effect curves and details related to the IC50 determinations are presented
in Supplementary Materials Figures S10–S15.
4. Conclusions
In the present study, we applied a two-step in silico screening (pharmacophore-based virtual
screening and docking simulations) followed by in vitro enzyme inhibition tests to identify a set of
new LmPTR1 inhibitors out of a large collection of chemically diverse natural products. The high
number of in vitro-confirmed inhibitors among the compounds identified in silico (15 active NPs out
of 18 tested compounds, corresponding to a hit rate of 83%) proved the validity of the employed
pharmacophore and docking-based virtual screening approach. This conclusion is additionally
augmented since each of the four different pharmacophore queries employed led to the identification
of NPs significantly inhibiting LmPTR1. An analysis of the results of the docking simulations implied
a similar pattern of interactions and binding mode of the identified inhibitors with the substrate binding
site of LmPTR1 comprising as an important feature pi–pi and H-bonding interactions with the bound
co-substrate, NADPH. This hypothesis has to be evaluated by further experiments, in particular,
a detailed investigation of the inhibition kinetics. Taken together, the inhibitors identified in this
study may represent promising starting points for the further development of more active inhibitors
of LmPTR1.
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